- A new coronavirus antibody treatment developed by AstraZeneca plc (NASDAQ:AZN) reduced the risk of developing the symptomatic disease by 77% compared to placebo.
- Related: AstraZeneca’s AZD7442 did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19.
- The trial included around 5,000 participants who did not have SARS-CoV-2 infection at baseline.
- More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination.
- The results of the Provent phase III pre-exposure prophylaxis trial showed there were no cases of severe COVID or COVID-related deaths in those treated with the “antibody cocktail” AZD7442.
- The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.
- In the placebo arm, there were three cases of severe COVID-19, which included two deaths.
- AstraZeneca said that the antibody combination, delivered through an injection to the muscle, could give people up to 12 months of protection from COVID-19.
- See: UK Approves Regeneron – Roche’s COVID-19 Antibody Cocktail
- It is the first non-vaccine antibody combination modified to provide potentially long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial, AstraZeneca added.
- AstraZeneca is now preparing the regulatory submission of the prophylaxis data to health authorities for potential emergency use authorization or conditional approval of AZD7442.
- Price Action: AZN shares are up 0.52% at $59.49 during the market session on the last check Friday.
AstraZeneca’s COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%
A new coronavirus antibody treatment developed by AstraZeneca plc (NASDAQ: AZN) reduced the risk of developing the symptomatic disease by 77% compared to placebo.
Related Posts
Canaan Q3 Adj. EPS $0.14 Beats $0.07 Estimate, Sales $137.51M Miss $151.64M Estimate
Canaan (NASDAQ:CAN) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 65.85 percent decrease over earnings of $0.41 per share from the same period
Morgan Stanley Initiates Coverage On PENN Entertainment with Equal-Weight Rating, Announces Price Target of $36
Morgan Stanley analyst Stephen Grambling initiates coverage on PENN Entertainment (NASDAQ:PENN) with a Equal-Weight rating and announces Price Target of $36.